Analyst
Piper Sandler
Equibles does not estimate personal net worth.
Adam Maeder is recorded as Analyst at Piper Sandler. Adam Maeder has spoken on 5 earnings calls across 4 companies, most recently for NYXOAH on March 19, 2026. Those appearances were for GLAUKOS Corp (GKOS), NYXOAH, Nyxoah SA (NYXH) and RxSight, Inc. (RXST). The companies whose calls Adam Maeder spoke on are classified in the Healthcare sector.
“The first one is just on, you know, some of the leading indicators or metrics that you shared, Olivier. If I heard correctly, you have 120 VAC submissions that were made, I think, as of December 31st last year, and I think 57 accounts activated.”
“The first one is just on, you know, some of the leading indicators or metrics that you shared, Olivier. If I heard correctly, you have 120 VAC submissions that were made, I think, as of December 31st last year, and I think 57 accounts activated.”
“And Mark, congratulations on the new role. Two from me, one on the guidance, one on international. So on the guidance front, wanted to ask, I guess, for a little bit more clarification just around sequencing of models.”
“Two for me, both on Eidos, and I'll ask them up front. So first on the re-implantation decision from FDA, if I heard it in the prepared remarks correctly, it's early 2026.”
“The first one is on IDOS re-implantation. I just wanted to see if there was any update there. I think you were planning to make a post-approval supplement submission to FDA in the first half of the year.”
Piper Sandler
Analyst
Source not stated
GKOS
Medical Devices · Healthcare
NYXOAH
Medical Devices · Healthcare
NYXH
Medical Devices · Healthcare
RXST
Medical Devices · Healthcare
FY 2025 financial results
NYXOAH
